Optimal pharmacologic treatment for chronic sciatica (CS) is currently unclear. While gabapentin (GBP) and pregabalin (PGB) are both used to treat CS, equipoise exists. Nevertheless, pharmaceutical regulation authorities typically subsidize one drug over the other. This hinders interchange wherever the favored drug is either ineffective or ill-tolerated.
C hronic sciatica (CS), like most neuropathic pain states, is often resistant to simple treatment regimens. 1, 2 Chronic sciatica is sciatica lasting longer than 3 months. 3 Neuropathic pain states are typically managed by superadding anticonvulsant drugs onto simple drug regimens. The drugs most commonly used are gabapentin (GBP) or pregabalin (PGB). Chronic sciatica has therefore been increasingly treated with super-added GBP or PGB. 1, 2, 4 Pregabalin and GBP are both analogs of γ-aminobutyric acid, a substance known to modulate calcium channel subunits. Both GBP and PGB may therefore possibly act by decreasing neurotransmitter release associated with central sensitization in CS and neuropathic pain.
Optimal pharmacological treatment for CS is unclear. In particular, the precise role of the 2 principal drugs, PGB or GBP, in treating CS has been surprisingly underexplored. 5 Thus, while GBP and PGB are both currently used to treat CS, a position of equipoise appears to exist regarding which to choose. 6 Notwithstanding, pharmaceutical regulation authorities across different countries typically subsidize one drug over the other. This hinders interchange wherever the favored drug is either ineffective or not tolerated. Paradoxically, in many countries, the drug favored for subsidy has actually been the more expensive regardless of whether PGB or GBP was chosen. 6 In 2017, a prospective randomized placebo-controlled clinical trial demonstrated a null effect for PGB in treating sciatica. 7 However, this study included patients recruited from multiple sources who experienced acute sciatica and CS; subgroup analysis specifically targeting CS was not performed. 7 Perhaps more importantly, no adequately powered direct headto-head study, which would compare PGB with any drug (including GBP), exists, to our knowledge.
Our study therefore represents the first prospective randomized cohort of patients with CS to comprehensively assess the head-to-head efficacy of PGB and GBP, the associated frequency and severity of adverse events (AEs), and the impact of PGB-GBP interchange.
Methods

Trial Design and Oversight
The study design used was a prospective, single-center, double-blind, randomized, double-dummy, crossover in patients with CS ( Figure) . The trial was conducted in accordance with the Standard Protocol Items: Recommendations for Interventional Trials statement and procedures following Good Clinical Practice principles. 8 The trial protocol has been published previously 9 and is available in open-access full text and in Supplement 1. The statistical analyses plan is available in Supplement 2. Ethics approval was by the Townsville Hospital and Health Service Human Research Ethics Committee. The trial was initiated by the investigators and funded by an internal hospital grant. No drug company had any involvement in drug supply, trial conduct, or manuscript review. Written informed consent was obtained before any procedures took place.
Eligibility and Recruitment
Patients with unilateral CS attending a specialist neurosurgery clinic in a large tertiary hospital were considered for trial recruitment. Chronic sciatica was defined as pain lasting for at least 3 months 3 radiating into 1 leg only to, at, or below the knee level. Imaging (magnetic resonance imaging with or without computed tomography) corroborating a root-level lesion concordant with symptoms and/or signs was determined by the trial clinician (L.A.G.M.). Inclusion criteria also included patients who had not used GBP and PGB, patients 18 years or older, and patients with a sufficient understanding of English (or an available appropriate interpreting service) to complete the study treatments and assessments. Concomitant medications (including analgesics) could be continued if the dose was stable 30 days prior to the start of the study. No more than 2 dose modifications were permitted throughout the study. Patients were excluded from the trial if they were pregnant, breastfeeding, or women planning conception during the study; had a history or diagnostic results that suggested an inherited neuropathy or neuropathy attributable to other causes (hypothyroidism, B 12 deficiency, connective tissue disease, amyloidosis, toxic exposure); had a major organ system disease; had cardiovascular autonomic neuropathy; had baseline postural hypotension of more than 20 mm Hg; had specific contraindications to PGB or GBP (allergy to or significant renal impairment); had cancer, dementia, severe mental illness, or other condition that would significantly reduce their ability to consent and/or fully undertake the program; and were unlikely to comply with study procedures (eg, those with high opiate/opioid tolerance, inconsistent clinic attendances). Because PGB and GBP are predominantly renally excreted, patients with an estimated creatinine clearance of less than 60 mL per minute were also excluded.
Randomization and Blinding
The trial pharmacist (K.R.) (unblinded/independent) generated the randomization code using a computer-derived permuted block with varying block size sequence. Manufacturing and preparation of the medication capsules was performed by an external Good Manufacturing Practice-accredited facility. The unblinded pharmacist was involved in preparing medication kits according to the trial randomization schedule. Treatment was allocated according to a 2 × 2 sequential design in which participants received PGB first, then subsequently GBP (or vice versa) in a double-blinded fashion. Owing to the variability in regular dosage frequency between the medications (PGB, twice daily and GBP, thrice daily) study medication packs contained 3 bottles, 1 for each dosage time (morning, lunch, and night) to maintain blinding. Medication packs for the PGB arm had a placebo incorporated as the lunch time dose such that both drug regimens were indistinguishable. The randomization schedule remained concealed from other researchers. The randomization process ensured concealed allocation and blinding of the specialist, the participant, and the outcome assessor during recruitment, data collection, and analysis.
Trial Regimen and Procedures
All patients were fully informed of the possible types of AEs associated with either GBP or PGB, as listed in the Australian Medicines Handbook, 10 prior to participation. Participants were randomized to commence treatment on either PGB or GBP. Because of the crossover design, participants had the unique opportunity to experience both PGB and GBP in succession. Because of the 1-week washout period, carryover effects (medium or long term) were considered improbable. Participants received standard neurosurgical care independent of and parallel to the trial. The starting dose of PGB was 150 mg once daily for the first week. This was titrated to the participant's optimal dose, up to a maximum of 300 mg twice daily, depending on their progress and tolerance at each dose level. The starting dose for GBP was 400 mg once daily for the first week. Likewise, this drug was titrated to the participant's optimal dose, up to a maximum of 800 mg thrice daily, depending on their progress and tolerance at each dose level. These doses are based on national recommendations from the Australian Medicines Handbook. 11 In the standard study dosing regimen, there was a 4-week titration period, after which the maximum tolerated dose for each participant was maintained for 4 weeks before the first study medication was ceased for washout. The washout period between treatment phases lasted for 1 week; this was deemed sufficient for these medications since they both possess a short half-life (5-7 hours). The dosage of either PGB or GBP could be amended at any stage in the trial based on efficacy and/or AE by communication between the study specialist and the study pharmacist. The maximum treatment period was 8 weeks for each medication. 10 Participants could continue concomitant medications (including analgesics) throughout the study, given the stipulations stated above. Such concomitant medications were closely monitored and recorded as part of the case report form. This practice is entirely consistent with National Institute for Health and Care Excellence-UK guidelines, which state that, when super-adding second-line agents for analgesic control (such as GBP and PGB), "overlap with first-line agents is encouraged to avoid decreased pain-control." 12 To our knowledge, only 1 prospective cohort study has reflected this practice with GBP in CS. 13 However, participants did not take concomitant medications that were contraindicated because of a known interaction with PGB or GBP. 11 No other pain interventions were permitted throughout the study; if considered necessary, such patients were withdrawn from the trial.
Outcomes and Data Collection
The primary outcome was leg pain intensity using the visual analog scale (VAS). Participants were asked to rate their average leg pain during the last 24 hours out of 10, with 0 representing no leg pain and 10 representing the worst pain imaginable. 4 A clinically important minimum difference of 1.5 points was chosen based on previous literature. 14 The key secondary outcome was the Oswestry Disability Index (ODI) questionnaire 4 to assess disability in which scores range from 0 to 100, with higher scores indicating greater disability. The clinically important difference is represented by 10 points. 15 Details of AEs were collected throughout the course of the trial and were noted as a description including a score of 0 to 10 for frequency and severity, whereby an increasing number denotes a higher frequency or severity. Outcomes were assessed at baseline, then at weeks 4, 8, 10, 14, and 18. Baseline and weeks 8, 10, and 18 were considered the primary times for the primary outcome that represented the start and finish of each medication.
Data collection was conducted by the study researchers from telephone, email, or online. Week 10 data collection served as the crossover secondary baseline for the purpose of analysis. Data were entered into case report forms by dedicated trained staff. Adherence to study medication was documented through a self-reported daily medication diary and by counting the returned medicine.
Statistical Analysis
It was estimated that a sample of 38 patients would be required to provide the trial with 80% power to detect a conservative minimum between-treatment difference of 0.9 points in the pain score on the 10-point scale at weeks 8 and 18 and to detect a clinically important between-treatment differ- Sequence AB is gabapentin (GBP) followed by pregabalin (PGB). Sequence BA is PGB followed by GBP.
ence of 10 points on the ODI at the same assessment interval. These assumptions included an SD of the difference between the 2 same values for the same patient of 1.2 points (given a crossover study design) and a 2-sided α level of .05. The estimated sample size would also allow for a dropout rate of 20%. As a result of our study representing the first head-tohead trial between PGB and GBP to our knowledge, an interim analysis was planned at 50% sample size to assess AEs and efficacy and to confirm trial viability. No formal stopping rules were used owing to the lack of previous head-to-head data enabling the presetting of boundaries. Instead, the investigators and independent trial monitor would make a judgment based on AEs and outcomes in the primary measure. Missing data were handled by a single imputation method whereby the last observation is carried forward and used as a surrogate for the missing value. This is the favored approach for replacing missing data as it is conservative, yields an appropriate estimate of variation in outcome, and is unlikely to bias toward the alternative hypothesis. 16 Data were deidentified prior to interim statistical analysis and performed on an intention-to-treat basis. Unadjusted means (SDs) were calculated and presented for descriptive statistics of the population. Normality of data distribution was assessed, and the appropriate t tests performed for betweengroups differences including repeated measures linear models. Binary variables were tested using χ 2 analysis. Statistical significance was set at a 2-sided P value of less than .05. The frequency and severity of AEs were reported descriptively with calculated mean (SD) based on unadjusted mean scores of patients. Data imputations were not required because less than 5% of the primary outcome data were missing. Analyses were performed using both Excel (Microsoft Inc) and SPSS statistical software version 22 (IBM Inc).
Results
Twenty participants underwent randomization from March 2016 to March 2018. This equated to 40 drug and patient episodes. Two patients were excluded. Ten patients were allocated to receive GBP followed by PGB, and 10 patients received PGB followed by GBP ( Figure) . After randomization, 2 patients were excluded from analysis. Both dropouts had been randomized to the GBP-then-PGB sequence. One patient did not collect study medication and was subsequently lost to follow-up. Each participant reached maximal dosing for the medications with less than 10% requiring any dose reductions (either temporary or permanent).
The total trial population (N = 18) experienced efficacy in VAS reduction and ODI reduction with the medication regimens. Twothirds (12 [67%] ) of the population reported at least 2 AEs while in the trial. More than half of the population (10 [55.6%]) were taking concomitant acetaminophen alone or in combination with codeine, while one-third (6 [33%] ) of the population were stable taking a background opioid before and during the trial ( 
Interchangeability
A total of 8 patients completed the GBP-then-PGB sequence, while 10 patients completed the PGB-then-GBP sequence (Table 4 ). Table 4 shows that GBP demonstrated superior efficacy in VAS reduction irrespective of the sequence order. Specifically, in the GBP-then-PGB sequence, there was a significantly greater mean VAS reduction associated with GBP than with PGB (mean [SD] eTable 2 in Supplement 3 shows that sequence order affected AEs only with PGB. Thus, while GBP AEs occurred at similar frequency irrespective of sequence order, PGB AEs were significantly affected by sequence order. Specifically, PGB AEs were doubled when PGB was prescribed first. Thus, there were 3 AEs for GBP and 21 for PGB in the PGB-then-GBP sequence compared with 4 for GBP and 10 for PGB in the GBP-then-PGB sequence.
Reduced ODI Efficacy in Those With AE eTable 2 in Supplement 3 shows that AEs specifically tended to affect ODI severity only with GBP. Specifically, efficacy was significantly less in those with AEs (GBP mean ODI reduction: with AEs, 9.33 [10.10] vs without AEs, 13.33 [9.85]; P = .04; eTable 2 in Supplement 3).
Discussion
The clinical trial protocol required the independent data monitor to review data after 50% of participants were recruited. The predetermined criteria for stopping the trial was a significant difference in recurrence rates or incidence of AEs between groups. Simultaneously, the trial would have considered to be stopped if any superiority was observed between the medications. After consultation in March 2018, the independent data monitor made a recommendation to the investigators that stopping the trial early was justified.
This predetermined interim analysis of this randomized clinical trial showed that while PGB and GBP were both significantly efficacious in reducing pain intensity in patients with CS, GBP was superior when compared head to head. Moreover, GBP was associated with fewer and less severe AEs irrespective of the sequence order. However, while PGB and GBP were both significantly efficacious in reducing painassociated disability (using ODI), neither were superior when compared head to head.
This clinical trial was adequately powered to detect a conservative difference between medications of 0.9 of 10 on the pain intensity score. We acknowledge the current clinically important treatment effect of 1.5 of 10 for pain intensity and 10 of 100 for disability severity. Our results showed that GBP was the only medication to show a clinically important difference in VAS reduction (mean [SD], 1.72 [1.17] ) and ODI reduction (mean [SD], 10.66 [9.90] ). Compliance with the medication regimen was high based on patient diaries and pill containers returned at each visit. Our selection criteria were based on an established definition of CS with 1 specialist neurosurgeon involved in screening and recruitment for consistency. The dose of the medications were adjusted using an increasing titration schedule with AE monitoring according to National Formulary recommendations. a Frequency and severity measured on a scale of 1 to 10 with 10 being the worst possible score.
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b The same participant may have experienced multiple adverse events of different descriptions.
c Gabapentin count was 7, and pregabalin count was 31 (P = .002).
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The crossover method chosen for this trial provides many advantages and particularly strengthens the study findings. In clinical trials, a crossover design should be limited to a disease that is long-term and stable and for which treatments should not result in a total cure but, instead, only alleviate the condition. Chronic sciatica and treatment with either PGB or GBP satisfied both these criteria, particularly considering that PGB and GBP are currently considered equivalent. This clinical trial therefore achieves a more efficient comparison of treatments than is possible with a parallel trial design. Any potential disadvantage relating to a carryover effect between medications in sequence was obviated by having set the washout period to more than 6 halflives of either PGB or GBP (effectively, 1 week).
Notably, this study showed that PGB AEs were more frequent and severe when PGB was taken prior to GBP. This suggests that GBP may in some way sensitize tissues such that, despite subsequent washout, tolerance to PGB AEs was significantly enhanced. If so, then putative PGB-induced sensitization did not appear to affect tissue tolerance to GBP; GBP AEs were significantly lower irrespective of sequence order. Given these findings, this study suggests that GBP should be commenced before PGB to permit optimal crossover wherever PGB may ultimately be warranted.
Limitations
There are limitations of this study. The low recruitment frequency reflects the difficulty associated with recruiting patients with CS who have not already been prescribed either PGB or GBP by practitioners in primary or tertiary care. Another limitation is the effects of treatment duration. The duration of the study for each participant is 8 weeks. In some rare cases, this might be considered insufficient time to test efficacy at the optimum dose. 4 Also, given the restricted doses and study time available in this study, it was not possible to introduce either drug in low and slow fashion. Because the latter potentially offsets the development of AEs, 4 this clinical trial may therefore potentially overestimate AEs with either drug. Moreover, the maximal dose of GBP prespecified in the study design is lower than what can be prescribed and was compared with the maximal dose of PGB. Last, maintenance of background therapies including prior analgesia is a limitation. This may affect both efficacy and AE development, potentially increasing both. However, this practice is entirely consistent with National Institute for Health and Care Excellence-UK guidelines 4, 12 and, indeed, standard clinical practice.
Conclusions
Pregabalin and GBP were both significantly efficacious. However, GBP was superior to PGB in reducing pain intensity and was associated with fewer and less severe AEs. Gabapentin should be commenced before PGB to permit optimal crossover.
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Background
Sciatica or sciatic neuralgia, a common form of lumbosacral radiculopathy, is characterised by low back pain which radiates to the leg and which may be accompanied by sensory loss, motor weakness and/or reflex abnormalities. Sciatica is a symptom defined as well-localised leg pain with a sharp, shooting or burning quality that approximates to the dermatomal distribution of the sciatic nerve down the posterior lateral aspect of the leg [1] . It is often associated with numbness or paraesthesia in the same distribution but typically extends beyond the limits of perceived pain in either a dermatomal or sclerotomal anatomical fashion [2, 3] . The term sciatica is used by clinicians in different ways: Some refer to any leg pain referred from the back as sciatica; others prefer to restrict the term to pain originating from the lumbar nerve root. Others believe sciatica is a form of 'neuropathic' pain caused by compression or irritation of the roots or nerves that comprise the sciatic nerve [1, 4] . Chronic sciatica (CS) is sciatica which has been present for more than 3 months despite active conservative management, including physical therapy. CS may complicate previous chronic low back pain; however, it may also present purely as an isolated phenomenon [1, 4] . The annual prevalence of sciatica varies widely (1.6-43%) with male predominance [4] . Sciatica accounts for 5% of patients with low back pain presenting to primary care practices and 30% have persistent pain for longer than 12 months. Of these 30% presenting to primary care, 20% are already out of work, and 5-15% require surgery. Over half of patients with sciatica will have pain 4 years post-diagnosis, and the socio-economic cost per country per year is estimated to be $128 million for inhospital care, $730 million for absenteeism and $708 million for disability [5] .
Anti-depressants such as tricyclic anti-depressants (TCAs; e.g., amitriptyline) are widely used to treat neuropathic pain (NP), including CS, as first-line therapy after failure of simple analgesics. On the basis of 'moderatequality' evidence, The National Institute for Health and Care Excellence -United Kingdom (NICE-UK) reported TCA efficacy over placebo for NP [6] ; however, on the basis of 'high-quality' evidence, TCAs were also significantly more likely than placebo to produce side effects (SEs). Extrapolating NICE-UK guidelines, prescribing authorities (e.g., Australian Therapeutic Guidelines [ATG]) often insist on trialling TCAs first for NP prior to introducing second-line agents. Limited information, however, is available regarding TCA use in CS. In one rare cross-over study, nortriptyline-alone or combined with morphine-had no significant benefit over placebo [6] .
Anti-convulsant anti-neuropathic agents such as gabapentin (GBP) and pregabalin (PGB) are also widely used to treat NP, including CS. On the basis of 'moderate-to high-quality' evidence, NICE-UK noted the efficacy of these agents over placebo for NP [6] . Australian prescribing authorities (e.g., ATG) recommend antineuropathic agents as second-line agents for NP, even though NICE-UK did not actually favour TCAs over anti-neuropathics as first-line agents (or vice versa). However, NICE-UK states that when introducing second-line agents, 'overlap' with pre-existent regimens should be considered to avoid decreased pain control [6] . A recent literature review provides information on the individual efficacy of PGB and GBP over placebo for CS; however, when compared head-to-head, no firm conclusions can be made [7] .
In summary, sciatica, like most NP states, often proves resistant to simple analgesic regimens (including paracetamol, non-steroidal anti-inflammatory drugs [NSAIDs] or opioids) and recommended first-line TCAs [1, 4] . Instead, the drugs most commonly used currently in both CS and NP are GBP or PGB [1, 4] . PGB and GBP are both analogues of γ-aminobutyric acid, a substance known to modulate calcium channel subunits. Both GBP and PGB may therefore possibly act by decreasing neurotransmitter release associated with central sensitisation in both CS and NP.
As with NP, there is currently an absence of highgrade evidence regarding the medical treatment of CS [1, 6] . No adequately powered direct 'head-to-head' trials comparing either PGB or GBP with other drugs are extant [1, 6] . Indirect comparisons, using placebo as the common comparator, have been published; however, each has represented differing patient populations, differing primary outcomes and differing pain measurement scales [6] . Authors of a recent review concluded, albeit based on weak evidence, that efficacy and SEs with GBP and PGB were probably similar [7] .
Notwithstanding this information, citing minor titration but definite cost advantages, NICE-UK nevertheless favoured PGB over GBP [6] . However, costs of either PGB or GBP vary widely globally. Moreover, costs vary unpredictably (i.e., PGB more expensive than GBP or vice versa) on a global basis [7] . Despite this, formulary regulatory authorities in most countries have, like NICE-UK, favoured one drug over the other. Furthermore, and somewhat paradoxically, formulary regulatory authorities in most countries have typically favoured the more expensive drug, whether GBP or PGB [7] . For example, GBP is currently available on the Australian Pharmaceutical Benefits Scheme (PBS) in Australia and some hospitals in the United Kingdom only for epilepsy; it is not listed for NP. PGB, by contrast, is subsidised on the PBS for NP. The U.S. Food and Drug Administration, along with Health Canada, have adopted reimbursement criteria similar to that of the Australian PBS; notwithstanding this, both GBP and PGB can be accessed in the United States and Canada via special access schemes (if patients satisfy stringent criteria for NP). In marked contrast, GBP is listed for use in treating both partial seizures and NP throughout Europe. The rulings of formulary regulators have therefore been inconsistent and dependent upon the individual body. Such action hinders interchange wherever the favoured drug is either ineffective or not tolerated [7] . Given that no evidence supports unhindered PGB-GBP interchange and that no study has directly challenged GBP and PGB head-tohead, neither GBP nor PGB should probably be favoured, given current evidence [7] .
Prospective 'head-to-head' studies are therefore urgently required to provide a robust evidence base for GBP or PGB use in sciatica [4] . Both medications have previously displayed efficacy when compared with placebo [1, 8, 9] . We therefore aimed to perform the first study to assess GBP and PGB directly head-to-head for treatment of CS.
Objectives
Primary objective and outcome
Our primary objective is to demonstrate if either GBP or PGB demonstrates superiority over the other in terms of efficacy for the treatment of patients diagnosed with CS. The co-primary outcome is leg pain intensity using a visual analogue scale (VAS) measured at baseline and at weeks 4, 8, 10, 14 and 18. The participants will be asked to rate their average leg pain over the last 24 h on a scale of 10, with zero representing 'no leg pain' and 10 representing the 'worst pain imaginable' [10] .
The co-primary outcome is the Oswestry Disability Index (ODI) [10] , measured at baseline and at weeks 4, 8, 10, 14 and 18, to assess disability. The Health Locus of Control Scale (HLOC) will also be used at baseline and at weeks 4, 8, 10, 14 and 18 to assess participants' decision-making processes because we have identified compliance with these medications as being low [10] .
Secondary objective and outcome
Our secondary objective is to demonstrate if one drug (i.e., either GBP or PGB) demonstrates superiority over the other in terms of the frequency and severity of SEs in the treatment of sciatica. The key secondary outcome will be the record of frequency and severity of SEs. Details of SEs will be collected at weeks 4, 8, 10, 14 and 18. The most common SEs of PGB are dizziness and somnolence [11] . The most common SEs of these medications are dizziness (27%), drowsiness (22%) and decreased memory (20%) [10] .
Methods/design
The Pregabalin and Gabapentin Prospective Clinical Trial for the Treatment of Sciatica: A Randomised, Double-Blind, Cross-over Study (PAGPROS) is a double-blind, randomised, double-dummy, cross-over trial comparing PGB with GBP for the treatment of CS (Fig. 1) . Ethics approval was obtained from the local human research ethics committee, and the study has been registered with the Australian and New Zealand Clinical Trials Registry (ANZCTR, 12613000559718). The study protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement [12] (Additional file 1), and a SPIRIT figure and CON-SORT diagram are provided in Figs. 1 and 2.
Participants and recruitment
Participants with unilateral CS will be recruited from attendance at a specialist neurosurgery clinic in a large tertiary hospital located in Townsville, Australia. The study specialists, comprising consultant neurosurgeons, will perform a medical evaluation to gain relevant medical and medication history and screen the patient against the eligibility criteria. This initial intervention will include baseline scores for VAS, ODI and HLOC. The patient will then be directed to the trial pharmacist, who will remain independent of the treating team, for consent and signature of the informed consent document.
Patients are deemed eligible if they meet all of the following criteria:
Pain radiating into one leg only to, at or below knee level Magnetic resonance imaging/computed tomography-confirmed sciatica caused by a degenerative condition (e.g., degenerative disc disease, bone spur growth, degenerative scoliosis) Naive to PGB and GBP use Aged 18 years or older Sufficient understanding of the English language or interpretation assistance available to complete the study treatment and assessments Concomitant medication, including analgesics and central nervous system CNS depressants (paracetamol, NSAIDs, and opioids), can be continued as long as the medication dose has been stable for 30 days prior to the start of the study.
Patients will be excluded if they meet any of the following criteria:
Pregnant or breastfeeding women or females planning conception during the study period Patient history or laboratory results that suggest the presence of inherited neuropathy or neuropathy Major organ system disease, diabetic cardiovascular autonomic neuropathy with abnormality in sympathovagal balance, baseline postural hypotension of more than 20 mmHg Specific contraindications to PGB or GBP (allergy to or significant renal impairment); PGB and GBP are both predominantly renally excreted, so patients with an estimated creatinine clearance < 60 ml/ minute will be excluded
Other neurologic medications such as serotonin reuptake inhibitors (paroxetine, fluoxetine), dual (serotonin and noradrenaline) reuptake inhibitors (venlafaxine), benzodiazepines, anti-convulsant medications (valproic acid, carbamazepine), anti--psychotic medications (clozapine, olanzapine, risperidone) or bipolar disorder medications (lithium) People with a diagnosis of cancer, dementia, severe mental illness or other condition which will significantly reduce the ability to consent and/or fully undertake the program
Diabetic and/or HIV-related neuropathies
If a patient is eligible, the unblinded independent trial pharmacist will gain informed consent and notify the research team. The participant will then be randomised, and the pharmacist will dispense and counsel on the study medications and arrange visit appointments with reminders. At this point, baseline data will be confirmed by the pharmacist as collected at the first visit, or subsequently via telephone, before the participant commences the study medication. Following baseline data collection, the researcher will instruct the participant to break the seal on the medication pack and commence the study medicine as per the dosage instructions. At this point, the participant is considered to have been included in the study.
To ensure consistency, the study researchers will ensure that the protocol is being followed and that good clinical practice is being monitored. General practitioners will be able to refer community patients into the trial via a trial specialist hotline contact number whereby the patient is screened by a study specialist to ensure consistency of enrolment.
Randomisation and blinding
The trial pharmacist (un-blinded) will generate a randomisation code using a computer-derived permuted block with varying block size sequence. Manufacturing and preparation of the medication capsules will be performed by an external good manufacturing practiceaccredited facility. The unblinded pharmacist will be involved in the preparation of the medication kits as per the randomisation schedule. The sequence will follow a 2 × 2 sequential design whereby participants will receive PGB first, then GBP (or vice versa), in a double-blinded fashion. Owing to the variability in regular dosage frequency between the medications (PGB twice daily, GBP thrice daily), study medication packs will contain three bottles each, correlating to the dosage times of morning, lunchtime and night, so as to maintain blinding. Medication packs pertaining to the PGB arm will have placebo incorporated as the lunchtime dose with all medications being indistinguishable. The randomisation schedule will remain concealed from other researchers. Placebo capsules will have an appearance identical to the active capsules. The randomisation process will ensure concealed allocation and blinding of the specialist, the participant and the outcome assessor.
Study treatment
Participants will be randomised to commence treatment on either PGB or GBP. As a result of the cross-over methodology, participants will have the opportunity to experience both PGB and GBP, and we predict little or no carry-over effects (medium-or long-term) after the washout period. We believe the incorporation of a stand-alone placebo arm is unethical in trials where participants with moderate to severe pain are recruited.
The starting dose of PGB is 150 mg once daily for the first week. This will be titrated to the participant's optimal dose up to a maximum of 300 mg twice daily, depending on their progress and tolerance at each dose level. The starting dose for GBP is 400 mg once daily for the first week. This will be titrated to the participant's optimal dose up to a maximum of 800 mg thrice daily, depending on their progress and tolerance at each dose level. These doses are based on national recommendations from the Australian Medicines Handbook [11] . In the standard study dosing regimen (Table 1) , we expect a 4-week titration period, after which the maximum tolerated dose for each participant will be maintained for 4 weeks before the first study medication is ceased in preparing for washout. The washout period between treatment phases will last 1 week, which is sufficient for these medications because they possess a short half-life (5-7 h). The dosage of either PGB or GBP can be amended at any stage in PAGPROS on the basis of efficacy and/or SEs by communication between the study specialist and the study pharmacist. The maximum treatment period is 8 weeks [13] .
The titration and dosage regimen are based on recommendations from clinical practice and medication guidelines such as the Australian Medicines Handbook and product prescribing information. Both medications have the potential for adverse neurological SEs, and hence a slow ascent in dose will contribute to mitigating this risk for participants and increasing compliance with the trial protocol. Simultaneously prior to washout, the dosage will be gradually reduced instead of being abruptly halted, further decreasing the likelihood of medication misadventures for the participants (and increasing compliance).
In addition to PGB or GBP, participants may continue concomitant medications (including analgesics) as long as the dosage has been stable for 30 days prior to commencing the study period. These concomitant medications will be closely monitored and recorded in the case report form (CRF). Medicines for NP include anti-depressants, selective serotonin and noradrenaline reuptake inhibitors, topical lignocaine and other anti-convulsant medications [14] . Note that this practice is entirely consistent with NICE-UK guidelines, which state that when super-adding second-line agents for analgesic control (such as GBP and PGB), 'overlap with first-line agents is encouraged to avoid decreased pain-control'. To our knowledge, only one prospective cohort study has reflected this practice with GBP in CS [14] . However, participants should not take concomitant medication that could result in an adverse interaction with PGB or GBP, including medicines that might increase the risk of excessive sedation (for example, benzodiazepines) [11] . No other pain interventions will be permitted throughout the study period; if considered necessary, then such patients will be withdrawn from PAGPROS.
Participating in PAGPROS is completely voluntary, and participants can stop taking part at any time without explanation or prejudice. Ceasing to participate in PAG-PROS may be considered, for example, wherever participants wish to explore the possibility of other treatments, including other medications or interventions (see above).
In some cases, participants may find that the starting dose of either PGB or GBP, whilst efficacious, produces unwanted SEs [10] . In such cases, a lower dose may be required, at least for a period of time. Because this cannot be accommodated within the current PAGPROS protocol, such patients will be removed from the study, and their data will be analysed as per intention-to-treat (ITT) principles; however, they may still form part of a prospective cohort for parallel study.
Data collection
Data collection will be conducted by the study researchers via telephone, email or online at baseline (before medication commencement) and at weeks 4, 8, 10, 14 and 18. Week 10 data collection will act as the cross-over secondary baseline for analysis purposes. Data will be entered into CRFs by dedicated trained staff. Each participant will receive up to seven face-to-face or telephone consultations with the trial pharmacist to commence treatment, monitor progress and adjust the dose of the study medication over the 8-week treatment periods. These visits will also incorporate a medical evaluation and collection of primary and secondary outcomes. Participants will receive usual neurosurgical care independent of and parallel to PAGPROS.
The use of prior and continued analgesic medicines will be collected at baseline. Adherence to study medication will be documented through a self-reported daily medication diary and by counting the returned medicine compared with the prescribed regimen as recorded by the trial pharmacist. Participants will be asked to return used and unused study medications at each visit.
Data integrity and analysis
The integrity of trial data will be monitored by regularly scrutinising data files for omissions and errors. We will perform double data entry of the primary and key secondary outcomes. The source of any inconsistencies will be explored and resolved. Electronic data will be stored on a secure server, and paper copies will be locked in a cabinet. Data will be accessible only by researchers, and participant confidentiality will be maintained through secure password-protected data storage during and after PAGPROS.
Data will be de-identified prior to statistical analysis, which will be performed on an ITT basis. Normality of data distribution will be assessed, and appropriate parametric (Student's t test or analysis of variance) or nonparametric (Wilcoxon signed-rank test, Wilcoxon rank--sum tests) tests for between-group differences will be performed. Statistical significance will be assessed at p < 0.05. Subgroup analysis may be implicated and considered as PAGPROS develops. Time-to-event analysis will be undertaken using Kaplan-Meier estimates on the week 8 and week 18 VAS scores. Missing data will be handled by a single imputation method whereby the last observation will be carried forward and used as a surrogate for the missing value. This method is the favoured approach for replacing missing data because it is conservative, yields an appropriate estimate of variation in outcome and is unlikely to bias towards the alternative hypothesis [15] . An alternative approach to missing data may be use of a longitudinal mixed-effects model incorporated into the analyses.
Sample size
We hypothesise that over an 8-week treatment period, GBP will reduce pain on the VAS scale by an average of 4.5 points from (7.5 to 3.0) as per historical literature [16] . We predict PGB to show at least the same benefit. We hypothesise that PGB will display superiority over GBP by at least a 20% better relative reduction in VAS score, with a resultant reduction of 5.4 (from 7.5 to 2.1) points from baseline. This 20% relative reduction is based on the average reduction of pain symptoms compared with placebo for indirect comparisons [1, 16] . Relative reduction will be used because it is often more impressive and also to allow for the instance of a lower-than-expected event rate, which would lower the absolute risk reduction. If the true difference in means of both arms of the study is 0.9 with an SD of 1.2, in order to detect this 20% relative decrease in pain between GBP and PGB, we will need to study 30 patients (15 per treatment arm) to reject the null hypothesis with 80% power. The type I error probability associated with this test of the null is 0.05. Assuming a 20% drop-out rate, the total sample size will be 38 patients (19 per treatment arm). We have chosen this large effect size and conservative SD on the basis of anecdotal and specialists' experience with this cohort of patients. The benefits of the cross-over methodology are evident with the small sample size required, owing to each participant acting as his/her own control. If this were a conventional parallel study design, the sample size needed would be approximately 100 participants. We conservatively estimate that if two people can be recruited per week, the study duration will be approximately 1.5 years.
Adverse experiences and monitoring
Potential risks of both PGB and GBP have been well studied owing to their use for neuropathic conditions. These risks have been minimised by our exclusion criteria. Any SEs will be monitored weekly during follow-up phone calls and examinations. Close monitoring of other neurological pain medications will be done with patient diaries. SEs were quantified in a latest metaanalysis and given the rare SEs of both medications and their likely effectiveness, and the potential benefits outweigh the risks in this study [1] .
During the recruitment period, a monitoring visit may be applicable. The responsible monitor will be a specialist neurosurgeon who is not involved in the conduct of the trial and is chair of the hospital patient safety committee. The purposes of monitoring are as follows:
To ensure that the study is conducted according to the protocol and applicable guidelines and regulations To verify source data against data on the CRF and in the database
To check the security of stored data To confirm that the consent process, approved by the Townsville Hospital Human Research Ethics Committee, has been followed and to view a random sample of original signed consent forms To review all serious adverse events (SAEs)
Interim data monitoring will take place in-house for review of safety and SEs. The trial may be stopped if more harm to patients is shown. The Pocock boundary will be used as the stopping rule, whereby after each set of 2n patient responses to a total of 'K' looks at the data. "2n" patient responses means there will be at least 2 interim analyses whereby the stopping rule can be enforced. This will be a group sequential approach whereby the critical boundary (p < 0.018) will be set at each look.
An adverse event is the appearance or worsening of any undesirable sign, symptom or medical condition occurring after starting the study, even if the event is not considered to be related to the investigational drug. Any SAE (defined as an event that is life-threatening or results in death, hospitalisation or significant disability) will be reported immediately to the relevant authorities (study monitor, ethics committee, data and safety monitoring board). If a potential relationship is suspected between the study drug and an SAE, then un-blinding to treatment allocation is indicated, and the participant will be withdrawn from PAGPROS.
Abnormal laboratory values or test results constitute adverse events only if they induce clinical signs or symptoms, are considered clinically significant or require therapy. The occurrence of adverse events should be sought by non-directive questioning of the patient at each visit during the study. Adverse events also may be detected when they are volunteered by the patient during or between visits or through physical examinations, laboratory tests or other assessments.
All adverse events will be recorded as follows:
Severity grade: mild, moderate or severe Relationship to investigational drug: suspected/not suspected Duration Continuation to an SAE All adverse events will be treated appropriately. The action taken to treat the adverse event should be recorded. An SAE is defined as follows:
Fatal or life-threatening Results in persistent or significant disability/ incapacity Constitutes a congenital anomaly/birth defect Requires inpatient hospitalisation or prolongation of existing hospitalisation
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the patient has provided informed consent and until 7 days after the patient has stopped study participation will be noted by expedited reporting to the Townsville Hospital and Health Service Human Research Ethics Committee.
Modification of the protocol
Any modifications to the protocol that may impact the design and conduct of the study will require a formal protocol amendment. Such amendment will be agreed upon by the study investigators and approved by the local ethics committee prior to implementation. Once approved, the changes will be communicated to the relevant parties.
Discussion
The PAGPROS protocol presents the design and rationale for a double-blind, double-dummy, randomised cross-over trial comparing the efficacy of PGB with GBP in treating CS. Owing to the variability in regular dosage frequency between the medications (PGB twice daily, GBP thrice daily), study medication packs will contain three bottles each, correlating to the dosage times of morning, lunchtime and night, to maintain blinding. Medication packs pertaining to the PGB arm will have placebo incorporated as the lunchtime dose, with all medications being indistinguishable.
Thus, PAGPROS represents the first head-to-head study to determine the relative role of either PGB or GBP in the evidence-based medical management of CS. However, in addition to efficacy, PAGPROS will also determine the frequency and severity of SEs with PGB or GBP. Thus, PAGPROS will determine the 'efficacy versus SE trade-off ' with each drug and whether differences in compliance rates result in consequences. For example, in a prior study with GBP in treating CS, 31% of patients ceased GBP within 1 week of treatment [10] . Moreover, efficacy was significantly less in those who experienced SEs in that study [10] .
In PAGPROS, we will employ the HLOC to assess psychological functioning with PGB or GBP in CS. In particular, PAGPROS will explore the prognosis of each drug relating to questionnaire outcomes relating to patients' insight into their psychological dysfunction. Thus, PAG-PROS may determine deficits and provide information not actually reported as SEs by the patients themselves. This may prove to be an important aspect of the study. For example, a prior prospective cohort study with GBP in treating CS revealed that, of 23 different SE types amongst 53% of patients, more than half could have adversely affected the ability to drive a motor vehicle safely or even to maintain employment [10] .
Finally, the double-blind cross-over design of PAGPROS may provide guidance regarding the implications of any potential need to substitute one drug for the other. For example, PAGPROS may determine whether SEs experienced with one drug are also observed with the other (i.e., in the same patient, in close temporal succession after cross-over). This may prove especially important should PAGPROS demonstrate a between-groups null effect regarding efficacy. However, PAGPROS may show significant efficacy to one drug but no efficacy to the other. Despite a lack of an evidence base, many formulary regulatory authorities worldwide typically favour one drug for subsidy over the other [4] . This hinders interchange wherever the favoured drug is either ineffective or not tolerated [4] . The nature of PAGPROS's design will directly assess the utility of cross-over between PGB and GBP and will therefore enable formulary regulatory authorities to make more informed therapeutic decisions than currently.
Recruitment commenced in early 2016, with data collection to be completed by mid 2018. The allocation concealment and double-blind design minimise bias, and data collection processes ensure data quality and integrity. The trial team has extensive experience in the design, conduct and reporting of clinical trials. Results of the study will be disseminated via publications and presentations.
Potential weaknesses of PAGPROS Treatment duration
PAGPROS permits a 4-week titration period, after which the maximum tolerated dose for each participant will then be maintained for 4 weeks. The duration of individual drug study is therefore 8 weeks. In some rare cases, this might be considered insufficient to test efficacy at the optimum dose [10] . Furthermore, because anecdotally some patients develop tolerance to SEs incurred with either PGB or GBP, the study period may also be too short to detect SE tolerance.
Dosages
Given the restricted doses and study time available in PAGPROS, it is not possible to introduce either drug in 'low and slow' fashion [4] . Because the latter potentially off-sets the development of SEs [4] , PAGPROS may therefore potentially over-estimate SEs with either drug. However, at least with GBP, there exists some control in that a prospective cohort study found SEs in 53% of patients with CS [10] .
Maintenance of background therapies including prior analgesia
This may affect both efficacy and SE development, potentially increasing both. However, note that this practice is entirely consistent with NICE-UK guidelines [6, 10] , and, indeed, standard clinical practice. NICE-UK guidelines state that, when super-adding second-line analgesic agents (such as GBP and PGB), 'overlap with first-line agents is encouraged to avoid decreased pain-control' [6] . To our knowledge, only one prospective cohort study has reflected this practice using GBP in CS [10] . • Data analysis will be performed by Mr Kelvin Robertson with oversight from the study epidemiologist.
• Questions regarding data analysis or statistical resources should be directed to Mr Kelvin Robertson.
• The SAP will be version controlled. Review and approval of the original, working version and any subsequent versions (e.g., amendments) will be documented per standard operating procedures.
• Members of the research team reviewed and approve the SAP.
Changes from protocol
• None
Changes from previous versions of SAP
STUDY OBJECTIVES
Primary objective
To demonstrate if either Gabapentin or Pregabalin demonstrates superiority over the other in terms of efficacy for the treatment of patients diagnosed with sciatica.
Secondary objectives
To demonstrate if one drug (i.e. either GBP or PGB) demonstrates superiority over the other in terms of the reduction in disability for patients suffering chronic sciatica.
Tertiary objectives
To demonstrate if one drug (i.e. either GBP or PGB) demonstrates superiority over the other in terms of the frequency and severity of adverse events in the treatment of sciatica.
STUDY DESIGN
Detailed power and sample size
We hypothesize that over an 8 week treatment period GBP and PGB will reduce pain on the VAS scale with the population average of 1.0 points based on historical literature. We are confident that PGB will display superiority over GBP by at least 20% better relative reduction in VAS score with a resultant average reduction of 1.9 points from baseline. This 20% relative reduction is based on the average reduction of pain symptoms compared to placebo for indirect comparisons. Relative reduction will be used as it is often more impressive and to cover for the instance of a lower than expected event rate which would lower the absolute risk reduction.
A total of 30 patients will enter this two-treatment cross-over study. The probability is 80% that the study will detect a treatment difference at a two-sided 0.05 significance level, if the true difference between treatments is 0.9 unit on the VAS scale. This is based on the assumption that the within-patient standard deviation of the response variable is 1.2. Assuming a 20% drop-out rate, we have decided to increase this sample figure to 38 patients and will provide enough power to prove the primary outcome. Past clinic figures allow the prediction of event rate for recruitment to be twice per week, which calculates to total study duration of approximately 1.5 years.
Baseline characteristics will be compared using Fisher's exact/Chi Square for dichotomous variables and ttest or Mann Whitney U test for continuous variables. The reduction of pain scores by individuals in the GBP and PGB groups will be compared using Fisher's exact/Chi Square (for a dichotomous outcome). Predefined subgroups will be analysed based on stratification within the randomisation. Time to event analysis will be undertaken using Kaplan Meier estimates. Comparison of GBP and PGB groups with regard to secondary outcomes will be conducted using independent samples t-test or Mann-Whitney U test for continuous data and chi-square or Fishers' exact test for categorical data. A two sided value of p < .05 will be considered to be statistically significant.
All data will be analysed on an intention to treat basis. Attempts will be made to continue to collect data on participants who discontinue the study medication. Patients who withdraw or are lost to follow up will be regarded as treatment failures for data analysis purposes. Missing data will be handled by a single imputation method. In this method, the last observation will be carried forward (LOCF) and will assume that this value will be a good surrogate for the missing value or is unlikely bias towards the alternative hypothesis. This is the favoured approach for missing data as it is conservative and yields an appropriate estimate of the variation in the outcome.
Randomisation
This is a single-center, phase IIIa/IIIb, randomised, double-blind, double dummy, sequential 2 x 2 cross-over clinical trial. Patients with confirmed diagnosis of sciatica and whom anti-neuropathic treatment would be an appropriate next phase in patient management will be recruited until the sample size of 38 is attained.
Each participant will receive an information sheet about the study and if they agree to participate, the participant will be given 1 week to sign the informed consent form. A member of the study team will contact the participant by phone the following day to follow-up consent. Alternatively, the participant can sign the consent form immediately.
The participant will be randomized to one of two sequences'; GBP then PGB or vice versa. Both interventions are proven medications to help treat sciatic pain. Drug will be supplied free of charge and the monitoring and care will have an increased stringency compared to non-participants on the same medications.
Permuted block randomisation will be performed to ensure that equal numbers of patients in each of the sequence groups in a 1:1 ratio. Permuted blocks of random lengths will be used. The randomisation sequence will be generated by the clinical trials pharmacist. The randomisation list will be kept in a secure password protected file until un-blinding. The contact details will be made available for un-blinding in emergencies and for sentinel event investigations.
Both interventions will be identical in appearance and obtained from the same manufacturer. Treatment allocation will be blinded at time of enrolment to treating doctor and patient. The enrolling doctor will complete the case report form and the patient will be dispensed study drug by an allocated pharmacist whom is unblinded to the study. Masking of allocated treatment will occur until all data are collected. Data will be unblinded for interim (if applicable) and at final analysis. Both the study investigators and the patients will be blinded to their randomisation. Publication will be sought from peer reviewed journal.
Study schema
STUDY VARIABLES AND COVARIATES
Primary outcome
The primary outcome i s leg pain intensity using the Visual Analogue Scale (VAS) measured at baseline and at weeks 4, 8, 10, 14 and 18. The participants will be asked to rate their average leg pain over the last 24hours out of 10, with zero representing 'no leg pain' , and 10 representing the 'worst pain imaginable
Secondary outcomes
The key secondary outcome is the Oswestry Disability Index (ODI) Questionnaire (13) , measured at baseline and at weeks 4, 8, 10, 14 and 18, to assess disability.
Tertiary outcomes
The tertiary outcome i s adverse event intensity using a 1-to 10 scale with 10 representing the 'most severe/frequent" adverse event imaginable. These will be collected at baseline and at weeks 4, 8, 10, 14 and 18.
Subgroups
Covariates
• Demographic and disease factors will be measured, including details on age, gender, smoking status, alcohol status, medical history and current medications.
Safety endpoints
• Adverse events attributable to the investigational medications outlined in section 4.3
Assessment schedule
• See section 4 and study schema.
ANALYSIS SETS
Intention to treat population
• All participants will be analysed in the group to which they were randomised.
DATA HANDLING
Data entry and audit
• All data will be entered into a Microsoft excel and SPSS database. An audit schedule of 1 patient's data per month will occur. If more than 0.5% entry error of non-text fields is discovered, another 2 patients will be randomly selected for inspection. If the error rate of the second sample is less than or equal to 0.5% then this process will stop. If the error rate of the second sample is more than 0.5% then the entire database will undergo 100% inspection. Errors found during the audit will be corrected in the database prior to any unblind analysis or data lock.
Data cleaning and database lock
• After the study has closed, data cleaning will be undertaken first by the data manager and then by the study statistician. This will include logic checks; examination of minimum, maximum values and frequency tables for out of range values; and percentage of missing values. All potential problems will be followed up with data queries. When there are no further data queries by the study statistician, the database will be locked. The final data set will reside in the study documents, in SPSS and Microsoft Excel.
STATISTICAL METHODS
The analysis of data for this study will be based on the objectives and outcomes outlined in the study protocol. Analyses will be conducted on locked study data using Microsoft Excel and SPSS Version 22.
General principles
• All tests will be two-sided.
• Statistical significance will be set at 0.05, unless specified.
• All statistics will include appropriate measures of uncertainty: standard deviations for descriptive statistics (or inter-quartile range for skewed data).
• All means and medians will be formatted to the specific journal requirements. Data will be de-identified prior to statistical analysis and performed on an 'intention-to-treat' basis.
Unadjusted mean±SD were calculated and presented for descriptive statistics of the population. Normality of data distribution was assessed, and the appropriate t-tests performed for between-groups differences including repeated measures linear models. Binary variables were tested using Chi-square analysis.
Statistical significance was set at a two-sided P value of less than 0.05. The frequency and severity of AE were reported descriptively with calculated mean±SD based on unadjusted mean scores of patients.
